Gilead/J&J NDA Could Mean Another Fixed-Dose Regimen For HIV
This article was originally published in The Pink Sheet Daily
Executive Summary
The pill combines J&J’s blockbuster protease inhibitor Prezista (duranavir) with Gilead’s boosting agent cobicistat. Currently, Prezista is required to be administered with the boosting agent ritonavir.